ãå»å¦çç 究ããåæ§æè ãæé¤ããã¦ãããããç 究è ãè¦è¨
ç±³å½ã®ããç 究è ãããå»å¦çç 究ã®ä¸ã«ã¯ãç§å¦çãªçç±ãªãã«åæ§æè ãç 究対象ããæé¤ãã¦ãããã®ããããã¨ããè¦è¨ãåãã¦ããã¨ãããã¥ã¼ã¹ã
ãã®æè¦ã¯2010å¹´3æ18æ¥çºè¡ã®ãNew England Journal of Medicineãèªã«æ²è¼ããããã®ã§ãå·çè ã¯ãã©ãã¯ã¹ã»ãã§ã¤ã¹ããã»ã³ã¿ã¼ï¼Fox Chase Cancer Centerï¼æå±ã®Brian Eglestonæ°ãRoland Dunbrack Jr.æ°ãMichael J. Hallæ°ã®3人ãå¤æ°ã®å»å¦çç 究ã§ã被é¨è ããç°æ§ã¨ã®ç¸äºçãªé¢ä¿ã«ãã人ãéå®ã¨ããã¦ãããã¨ãåé¡è¦ããå 容ã ã¨ã®ãã¨ã
ãªãã§ããç·å¥³éã®HIVææã«ã¤ãã¦ã®ç 究ãªã©ã被é¨è ããããéå®ã«ããç§å¦çæ ¹æ ãããç 究ãªãã¾ã ããã
- 注ææ¬ é¥é害ã®è¬ã®å®é¨
- åç«è ºããæè¡å¾ã®åèµ·é害ã«ã¤ãã¦ã®ç 究
- ç³å°¿ç ããã¤ç ãè¯æ§åç«è ºè¥å¤§çãªã©ã«é¢é£ããæ§æ©è½ã®ç 究
ãªã©ãåæ§æè ã被é¨è ããæé¤ããçç±ãä¸æçãªç 究ã§ããããã£ãæé¤ãè¡ããã¦ãããã ããã§ããã
ãã®3人ã¯ãããã»ã³ã¿ã¼ã®è¨åºè©¦é¨ã®è¢«é¨è åç°¿ãè¦ã¦ãã¦ãã®äºå®ã«æ°ã¥ããã¨ã®ãã¨ããã®å¾æ¿åºã®ãã¼ã¿ãã¼ã¹ã®ä½åãã®ç 究ã«ã¤ãã¦æãåã調æ»ãããã¨ããããã£ã¨ããããã®ä¾ãè¦ã¤ããããã®å¤ãã¯ç§ä¼æ¥ã«ããç 究ã ã£ãããã§ãã
ã¡ãªã¿ã«Eglestonæ°ã«ããã¨ãç±³å½ã§ã¯é£é¦æ¿åºã«ç 究費ãæ±ããç 究è ã¯ãã¸ã§ã³ãã¼ã»äººç¨®ã»æ°æãªã©ã«ãã£ã¦ç¹å®ã®éå£ãç 究ããé¤å¤ããçç±ã説æãã義åããããã®ã®ãæ§çæåã«ãã£ã¦è¢«é¨è ãé¤å¤ããçç±ã説æããå¿ è¦ã¯ãªãã®ã ããã§ããã¾ããç 究è ã¯å è¡ç 究ã®åºæºããã«ããï¼ãã¼ã¹ããããå¾åããããããåããããªæé¤ãç¶ãã¦ãã¾ãå¯è½æ§ãããã®ã ã¨ãã
ã²ã¨æåã¯ãå»å¦çç 究ãã女æ§ãæé¤ããã¦ãããã¨ãåé¡è¦ããã¦ããã¨æãã¾ããç·æ§ã®ä½ãå¥åº·ã«ã¤ãã¦ã®ã¿èª¿ã¹ã¦ããããã人éã®ãå¥åº·ã§ãããã人éã®ãä½ã¯ãããªã£ã¦ãã¾ããã¨çµè«ã¥ãããã¨ãçåè¦ãããåãã¦ç·æ§ã¨å¥³æ§ã®ççå¦çãªéãã念é ã«ãããç 究ãè¡ãããããã«ãªã£ã¦ãããããããã¾ããã§ããã£ãã
ã§ããã²ã¤ãã¬ãºãã¢ã³ã¯ãã¾ã ã人éãã«å«ãã¦ããã£ã¦ãªããã§ããã
æå³ã®ãªãæé¤ãæ©ããªããªã£ã¦ãããããç¥ãã¾ãã
åèªã»èªå¥ãªã©
åèªã»èªå¥ | æå³ |
---|---|
fluke | ãããã¯ãå¶ç¶ã®ã§ããã¨ãã¾ããããã |
self-perpetuating | æ°¸ç¶å¯è½ãªããã¤ã¾ã§ãã¨ã©ã¾ããç¡æéã«ç¶ç¶ããã |
criteria | criterionï¼æ¨æºãåºæºãç¹å¾´ï¼ã®è¤æ°å½¢ |
turn up | ï¼ç¥å¼ï¼ï¼äºå®ãªã©ï¼ãçºè¦ãããæ¢ãåºã |
oversee | ç£ç£ããããã£ãã[å¶ç¶]è¦ããè¦æ¸¡ããæ¦è¦³ãã |
enrolment | è¨è¼ãç»é²ãç»é²ç°¿ãç»é²è åç°¿ |
clinical trial | è¨åºè©¦é¨ |
spot check | æãåãæ¤æ»ãæãæã¡æ¤æ» |